P1038 TL-895, A first-in-class, covalent bruton tyrosine kinase inhibitor (BTKI) for the treatment of myelofibrosis (MF) patients (PTS) with severe thrombocytopenia (platelets (PLTS)<50 K/UL)

Absztrakt
Leírás
Kulcsszavak
Forrás
HemaSphere. -7 : Suppl_3 (2023), p. 1983-1985. -Hemasphere. - 2572-9241